How has Bayer Cropscience Limited (BAYERCROP) been performing? We dig into revenue, profitability, valuation, and ownership trends.
Bayer Cropscience Revenue Trend
Year-over-year, Bayer Cropscience Limited grew revenue by 8.6% — from ₹4,892 Cr in FY2024 to ₹5,314 Cr in FY2025.
The 10-year revenue CAGR of 3.6% is on the lower side. Bayer Cropscience Limited's top line moved from ₹3,723 Cr to ₹5,314 Cr, but real growth has been thin.
A ₹5,314 Cr revenue base makes Bayer Cropscience Limited a mid-sized name in the Indian pesticides and agrochemicals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹5,314 Cr | +8.6% |
| FY2024 | ₹4,892 Cr | -1.1% |
| FY2023 | ₹4,945 Cr | +8.0% |
| FY2022 | ₹4,577 Cr | +5.8% |
| FY2021 | ₹4,325 Cr | — |
View Bayer Cropscience Limited's full 10-year revenue trend with CAGR analysis →
Bayer Cropscience Profitability
Profitability was under pressure with net income dropping 23.3% to ₹568 Cr in FY2025.
The net margin narrowed from 15.1% to 10.7%, suggesting rising cost pressures.
On a per-share basis, diluted earnings were ₹126.38 in FY2025 versus ₹164.77 in FY2024.
Is Bayer Cropscience Undervalued
The P/E Ratio approach puts Bayer Cropscience Limited's intrinsic value at ₹4,506, a 9.9% upside from the current market price.
Bayer Cropscience Limited shares are currently trading at ₹4,099.80.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹4,506 | 9.9% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Bayer Cropscience Limited with detailed assumptions →
Bayer Cropscience Shareholding Pattern
The promoter group has maintained its 71.4% holding through the last 4 quarters.
Foreign institutions moved their stake up to 3.9% from 3.6% over the past year.
Domestic institutional investors (DIIs) held 11.9% as of March 2026, up from 11.4% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 71.4% | 3.9% | 11.9% | 12.8% |
| Dec 2025 | 71.4% | 3.8% | 11.5% | 13.3% |
| Sep 2025 | 71.4% | 3.8% | 11.2% | 13.6% |
| Jun 2025 | 71.4% | 3.6% | 11.4% | 13.6% |
Track quarterly shareholding changes for Bayer Cropscience Limited →
Bayer Cropscience Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹52.46B at the end of FY2025, up 14.1% from ₹45.97B a year earlier.
Inventories is the largest block at 45.0%, followed by Receivables at 18.1% and Cash & ST Investments at 17.6%.
Equity makes up 54.3% of liabilities and equity, with debt at 2.0% and operating liabilities at 43.7%. Over the year, debt is up 123.1% and equity is up 0.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 9.21B |
| Receivables | 9.52B |
| Inventories | 23.62B |
| Property, Plant & Equipment | 4.27B |
| Intangibles & Goodwill | 1.36B |
| Other Assets | 4.47B |
| Category | Value |
|---|---|
| Equity | 28.50B |
| Short-term Debt | 435.00M |
| Long-term Debt | 616.00M |
| Trade Payables | 10.98B |
| Other Liabilities | 11.92B |
Bayer Cropscience Key Highlights
Bringing the key threads together for Bayer Cropscience Limited (BAYERCROP) as a pesticides and agrochemicals investment opportunity.
Revenue of ₹5,314 Cr in FY2025, up 8.6% year-over-year.
Long-term revenue has been compounding at 3.6% annually over 10 years.
The company is profitable, with a net margin of 10.7% and net income of ₹568 Cr.
The P/E Ratio model implies 9.9% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Bayer Cropscience Limited.